ChemoCentryx Inc expected to post a loss of 50  cents a share - Earnings Preview

Churchill Capital XI

25/02/2022 11:54

* ChemoCentryx Inc  CCXI.OQ   CCXI.O  is expected to show a
rise
in quarterly revenue when it reports  results on March 1. 
    * The San Carlos California-based  company is expected to
report 
a 166.7% increase in revenue to $11.622 million from $4.36
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ChemoCentryx Inc is
for a
loss of 50 cents per share. For the same quarter last year, the
company reported a loss of 43 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for
ChemoCentryx Inc
is $64.5​, about 54.4% above​ its last closing price
of $29.43. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.44       -0.45      -0.32     Beat    28.3
 Jun. 30 2021  -0.54       -0.54      -0.56     Missed  -2.8
 Mar. 31 2021  -0.42       -0.40      -0.43     Missed  -6.2​
 Dec. 31 2020  -0.34       -0.33      -0.43     Missed  -29.2
 ​​Sep.        -0.31       -0.31      -0.35     Missed  -12.4
 30 2020                                                
 Jun. 30 2020  -0.34       -0.34      0.29      Beat    185.3​
 Mar. 31 2020  -0.30       -0.30      -0.35     Missed  -16.7
 Dec. 31 2019  -0.25       -0.26      -0.26     Met     0.6
 This summary was machine generated February 25 at 11:54 GMT. 
All figures in US dollars  unless otherwise stated